Natco Pharma Ltd stated that it has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19.
The company said that with this licence agreement, it can manufacture and sell Molnupiravir capsules 200 mg for Indian market, which will be sold under brand name MOLNUNAT for treatment of COVID-19 infection in patients.
Under the licence, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD,'' the company said.
Drugs Controller General of India (DCGI) had allowed anti-COVID-19 pill Molnupiravir for emergency use in the country.
Rajasthan: Former OSD To Ashok Gehlot, Lokesh Sharma Granted Bail In Gajendra Singh Shekhawat Phone Tapping Case
'We Only Believe On Jassi Bhai, Miyan...': Rishabh Pant Pokes Fun At Mohammed Siraj's English After AUS vs IND 1st Test
SEBI To Auction 17 KBCL India Properties Worth ₹4.23 Crore On December 23
Ram Gopal Varma To Appear 'Digitally' For Probe Over Offensive Posts Against Andhra Pradesh CM Chandrababu Naidu
(With inputs from PTI)
